In addition, Cho et al. showed that TPCK, a TNF-α inhibitor, could reduce ovarian cancer invasiveness, suggesting that TAM-derived TNF-α promoting cancer invasion is a common event in tumor progression [104]. Here, TNF is linked to ovarian cancer.